22 related articles for article (PubMed ID: 38451831)
1. [Incidence of common gene mutations in early-onset colorectal cancer and the association with cancer survival: a meta-analysis].
Zhang RQ; Li SH; Hu TJ; Xu LY; Zhu YS; Li X
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 May; 27(5):495-506. PubMed ID: 38778689
[TBL] [Abstract][Full Text] [Related]
2. Tissue Elasticity as a Diagnostic Marker of Molecular Mutations in Morphologically Heterogeneous Colorectal Cancer.
Plekhanov AA; Kozlov DS; Shepeleva AA; Kiseleva EB; Shimolina LE; Druzhkova IN; Plekhanova MA; Karabut MM; Gubarkova EV; Gavrina AI; Krylov DP; Sovetsky AA; Gamayunov SV; Kuznetsova DS; Zaitsev VY; Sirotkina MA; Gladkova ND
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791375
[TBL] [Abstract][Full Text] [Related]
3. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy for
Güttlein L; Luca MR; Esteso F; Fresno C; Mariani J; Otero Pizarro M; Brest E; Starapoli S; Kreimberg K; Teves P; Mendoza Bertelli A; R Girotti M; Salanova R; O'Connor JM
Future Oncol; 2022 Sep; 18(29):3277-3287. PubMed ID: 36004810
[No Abstract] [Full Text] [Related]
5. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Aranda E; Salazar R
Ann Oncol; 2019 May; 30(5):796-803. PubMed ID: 30840064
[TBL] [Abstract][Full Text] [Related]
6. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
8. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
9. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.
Cicenas J; Tamosaitis L; Kvederaviciute K; Tarvydas R; Staniute G; Kalyan K; Meskinyte-Kausiliene E; Stankevicius V; Valius M
Med Oncol; 2017 Feb; 34(2):26. PubMed ID: 28074351
[TBL] [Abstract][Full Text] [Related]
10. Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
